BioWorld

Jan. 16, 2008

XenoPort's RLS Drug Reduces Relapse Rate In Phase III Trial

Genentech Earnings Just OK, 'Flattish' 2008 Ahead: Analyst

Pervasis Gets $9.75M to Boost Blood Vessel Repair Candidate

Alfacell Deals U.S. Rights for Onconase to Strativa

Alfacell Corp. licensed U.S. commercialization rights for the Phase III cancer drug Onconase (ranpirnase) to Strativa Pharmaceuticals in a deal worth up to $225 million. (BioWorld Today) Read More

Novo Nordisk Halts Development of its Inhaled Insulin Program

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 27, 2026.

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 24, 2026